aminolevulinic acid has been researched along with Multiple Primary Neoplasms in 6 studies
Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.
5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Photodynamic therapy (PDT) using topical delta-aminolevulinic acid (delta-ALA) is an effective treatment for Bowen disease and certain basal cell carcinomas (BCCs), but its place in clinical practice remains to be established." | 5.09 | Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma. ( MacKie, RM; McColl, JH; Moore, JV; Morton, CA; Whitehurst, C, 2001) |
| "No new basal cell carcinomas were observed during the 8-month follow-up period in areas treated with a broad application technique." | 2.42 | delta-Aminolevulinic acid and blue light photodynamic therapy for treatment of multiple basal cell carcinomas in two patients with nevoid basal cell carcinoma syndrome. ( Gilchrest, BA; Itkin, A, 2004) |
| "Patients with nevoid basal cell carcinoma syndrome suffer from multiple basal cell carcinomas, requiring numerous surgical procedures that over time leave them with multiple disfiguring scars." | 2.42 | delta-Aminolevulinic acid and blue light photodynamic therapy for treatment of multiple basal cell carcinomas in two patients with nevoid basal cell carcinoma syndrome. ( Gilchrest, BA; Itkin, A, 2004) |
| "We report treatment of two nevoid basal cell carcinoma syndrome patients, women aged 21 and 47, with 20%delta-aminolevulinic acid solution and 417-nm blue light source (irradiance 10 mW/cm(2))." | 2.42 | delta-Aminolevulinic acid and blue light photodynamic therapy for treatment of multiple basal cell carcinomas in two patients with nevoid basal cell carcinoma syndrome. ( Gilchrest, BA; Itkin, A, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Miguélez, A | 1 |
| Martín-Santiago, A | 1 |
| Bauzá, A | 1 |
| Gilaberte, Y | 1 |
| Fai, D | 1 |
| Arpaia, N | 1 |
| Romano, I | 1 |
| Vestita, M | 1 |
| Cassano, N | 1 |
| Vena, GA | 1 |
| Alloo, A | 1 |
| Garibyan, L | 1 |
| LeBoeuf, N | 1 |
| Lin, G | 1 |
| Werchniak, A | 1 |
| Hodi, FS | 1 |
| Flaherty, KT | 1 |
| Lawrence, DP | 1 |
| Lin, JY | 1 |
| Kamp, MA | 1 |
| Santacroce, A | 1 |
| Zella, S | 1 |
| Reichelt, DC | 1 |
| Felsberg, J | 1 |
| Steiger, HJ | 1 |
| Cornelius, JF | 1 |
| Sabel, M | 1 |
| Itkin, A | 1 |
| Gilchrest, BA | 1 |
| Morton, CA | 1 |
| Whitehurst, C | 1 |
| McColl, JH | 1 |
| Moore, JV | 1 |
| MacKie, RM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Single Center Phase II Trial of Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation[NCT01474551] | Phase 2 | 2 participants (Actual) | Interventional | 2011-11-30 | Terminated (stopped due to Lack of accrual) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 will be used to determine treatment response. In order to be considered evaluable for response, a patient must have completed at least 1 cycle of therapy. Patients who do not complete a cycle of therapy can be replaced. (NCT01474551)
Timeframe: 2 years
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Stable Disease | Complete Response | Partial Response | Progression of Disease | |
| Vemurafenib | 1 | 0 | 0 | 0 |
1 review available for aminolevulinic acid and Multiple Primary Neoplasms
| Article | Year |
|---|---|
delta-Aminolevulinic acid and blue light photodynamic therapy for treatment of multiple basal cell carcinomas in two patients with nevoid basal cell carcinoma syndrome.
Topics: Adult; Aminolevulinic Acid; Basal Cell Nevus Syndrome; Carcinoma, Basal Cell; Female; Humans; Middle | 2004 |
2 trials available for aminolevulinic acid and Multiple Primary Neoplasms
| Article | Year |
|---|---|
Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma.
Topics: Aged; Aminolevulinic Acid; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease Progression; Dru | 2012 |
Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Female; | 2001 |
3 other studies available for aminolevulinic acid and Multiple Primary Neoplasms
| Article | Year |
|---|---|
Urticaria-like reaction secondary to photodynamic therapy in 2 pediatric patients.
Topics: Aminolevulinic Acid; Basal Cell Nevus Syndrome; Child; Child, Preschool; Female; Humans; Neoplasms, | 2013 |
Methyl-aminolevulinate photodynamic therapy for the treatment of actinic keratoses and non-melanoma skin cancers: a retrospective analysis of response in 462 patients.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Carcinoma, Squ | 2009 |
Is it a glioblastoma? In dubio pro 5-ALA!
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Brain Neoplasms; Diagnosis, Differential; Femal | 2012 |